Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies.

摘要

Clofarabine-containing combination regimens are under evaluation for patients with relapsed or refractory leukaemia (Faderl et al, 2005; Hijiya et al, 2009; Locatelli et al, 2009;O'Connor et al, 2011). We report our single-institution experience with clofarabine, cyclophosphamide, and etoposide (CCE) combination therapy in children with relapsed or refractory haematological malignancies. Informed consent for treatment was obtained, and the study was approved by our institutional review board.